Opiant Pharmaceuticals (OPNT) – FDA
-
Opiant Pharmaceuticals (OPNT) Announces FDA Acceptance and Priority Review of NDA for OPNT003
-
Opiant Pharmaceuticals (OPNT) Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to OPNT Stock Lookup